Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
| $211.00 | |
| A02037-40 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Specificity | The product is specific for Ranibizumab. |
| Host Species | Rabbit |
| Immunogen | Ranibizumab |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid repeated freezing and thawing cycles. |
| Purification | Antigen affinity purification |
| Isotype | Rabbit IgG |
| Clonality | Polyclonal |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
ELISA binding of Anti-Ranibizumab Antibody, pAb, Rabbit (GenScript, A02037-40) with Ranibizumab.
Coating antigen: Ranibizumab, 1 µg/ml.
Anti-Ranibizumab Antibody, pAb, Rabbit (GenScript, A02037-40) dilution start from 1,000 ng/ml.
EC₅₀= 29.68 ng/ml.
»
| Target Background | Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity. GenScript Anti-Ranibizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ranibizumab. |
| Synonyms | Mouse monoclonal to Lucentis |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
